Lupin shares gain ahead of US drug launch that can
With this launch, Lupin’s FY26 revenue opportunity is estimated at $150–200 million. gTolvaptan could contribute over 25% to Lupin’s FY26 earnings.
Source
<meta name="google-adsense-account" content="ca-pub-6363428395369086">
- Sun TV Dispute: Dayanidhi Maran Sends Legal Notice To Kalanithi
- A good monsoon: Despite a dwindling share, agriculture could buttress